A Phase 3 interventional study of DTG/3TC and Cabotegravir (CAB) LA in HIV Infections, sponsored by ViiV Healthcare. Completed at 47 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 22nd largest by enrollment, is one of 5 that started in 2023, is one of 21 in phase 3, and was the 47th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 74th largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2023, is one of 65 in phase 3, and was the 235th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies. The study will investigate two 2-drug regimens for the treatment of HIV-1: a fixed-dose combination oral tablet of dolutegravir/lamivudine (DTG/3TC) and cabotegravir plus rilpivirine long-acting agents (CAB + RPV LA). All participants will initially receive DTG/3TC once daily, and once virologic suppression is attained (plasma HIV-1 \<50 c/mL), participants will be offered a choice to switch to CAB + RPV LA or to continue taking oral DTG/3TC. This study will provide important data on the efficacy, safety, implementation effectiveness, and patient-reported outcomes of these two regimens in a study where participants have the option to choose between them based on individual preference. The aim of the study is to evaluate the antiviral effectiveness at 11 months after switching to CAB+RPV LA following initial virologic suppression on DTG/3TC and to provide data on how long it takes participants to suppress their viral load on DTG/3TC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence of virus (HBV) infection based on the results of testing at Screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), and hepatitis B surface antibody (anti-HBs) as follows:
Participants with virus (HCV) co-infection at Screening are eligible only if:
Participants with treatment with any of the following agents within 28 days of Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DTG/3TC
Drug: Cabotegravir (CAB) LA · Drug: Rilpivirine (RPV) LA
Drug pages: Dolutegravir · Lamivudine
DTG/3TC FDC will be administered as an oral once daily tablet.
Also known as: Dovato
CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
Also known as: Vocabria
RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
Also known as: Rekambys
[DTG/3TC]: Time to Virologic Suppression (HIV-1 Ribonucleic Acid [RNA] <50 Copies per Millilitre [c/mL]) From Baseline (Day 1)
Time frame: Baseline (Day 1) up to Month 12
[CAB + RPV LA]: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL as per Snapshot Algorithm at Month 11
Time frame: Month 11
[DTG/3TC]: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL as per Snapshot Algorithm at Month 12
Time frame: Month 12
[DTG/3TC]: Percentage of Participants With Plasma HIV-1 RNA Greater Than or Equal to (>=) 50 c/mL as Per Snapshot Algorithm
Time frame: Month 12
[CAB + RPV LA]: Percentage of Participants With Plasma HIV-1 RNA >= 50 c/mL as Per Snapshot Algorithm
Time frame: Month 11
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL and <200 c/mL Through Day of Choice
Time frame: Up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL and <200 c/mL Over Time
Time frame: Up to and including Month 12
[CAB + RPV LA]: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL and <200 c/mL Over Time
Time frame: Up to and including Month 11
Absolute Values for Plasma HIV-1 RNA (log10 c/mL) Through Day of choice
Time frame: Up to and including Day of Choice (approximately 20 weeks)
Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) Through Day of Choice
Time frame: Baseline (Day 1) and up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Absolute Values for Plasma HIV-1 RNA (log10 c/mL) Through Month 12
Time frame: Up to and including Month 12
[DTG/3TC]: Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) Through Month 12
Time frame: Baseline (Day 1) and up to and including Month 12
Absolute Values in Cluster of Differentiation 4 (CD4+) Cell Count Through Day of Choice
Time frame: Up to and including Day of Choice (approximately 20 weeks)
Change From Baseline in CD4+ Cell Count Through Day of Choice
Time frame: Baseline (Day 1) and up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Absolute Values in CD4+ Cell Count Through Month 12
Time frame: Up to and including Month 12
[DTG/3TC]: Change From Baseline in CD4+ Cell Count Through Month 12
Time frame: Baseline (Day 1) and up to and including Month 12
[CAB + RPV LA]: Absolute Values of CD4+ Cell Count Through Month 11
Time frame: Up to and including Month 11
[CAB + RPV LA]: Change From Baseline in CD4+ Cell Count Through Month 11
Time frame: Baseline (Day 1) and up to and including Month 11
Percentage of Participants Meeting Confirmed Virologic Failure (CVF) Criteria Through Day of Choice
Time frame: Up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Percentage of Participants Meeting CVF Criteria Over Time
Time frame: Up to and including Month 12
[CAB + RPV LA]: Percentage of Participants Meeting CVF Criteria Over Time
Time frame: Up to and including Month 11
Percentage of Participants With Disease Progression Through Day of Choice
Time frame: Up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Percentage of Participants With Disease Progression Over Time
Time frame: Up to and including Month 12
[CAB + RPV LA]: Percentage of Participants With Disease Progression Over Time
Time frame: Up to and including Month 11
Percentage of Participants With Viral Resistance to CAB, RPV, DTG and 3TC Through Day of Choice
Time frame: Up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Percentage of Participants With Viral Resistance to CAB, RPV, DTG and 3TC Through Month 12
Time frame: Up to and including Month 12
[CAB + RPV LA]: Percentage of Participants With Viral Resistance to CAB, RPV, DTG and 3TC Through Month 11
Time frame: Up to and including Month 11
Percentage of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AEs) and AEs Leading to Discontinuation of Study Intervention Through Day of Choice
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function which meets the definition of Hy's Law.
Time frame: Up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC] Percentage of Participants With SAEs, Drug Related AEs and AEs Leading to Discontinuation of Study Intervention Over Time
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function.
Time frame: Up to and including Month 12
[CAB + RPV LA] Percentage of Participants With SAEs, Drug Related AEs and AEs Leading to Discontinuation of Study Intervention Over Time
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function.
Time frame: Up to and including Month 11
Change From Baseline in Total Treatment Satisfaction Score for HIV Treatment Satisfaction Status Questionnaire (HIVTSQs) to Day of Choice
HIVTSQ is a 12-item self-reported scale. Individual items are rated from 0 (very dissatisfied) to 6 (very satisfied) producing a total score ranging from 0 to 66. Higher scores indicate a greater level of participant-reported satisfaction with their current therapy
Time frame: Baseline (Week 4) up to Day of Choice (approximately 20 weeks)
Change From Baseline in Individual Item Score for HIV Treatment Satisfaction Status Questionnaire (HIVTSQs) to Day of Choice
HIVTSQ is a 12-item self-reported scale. Individual items are rated from 0 (very dissatisfied) to 6 (very satisfied).
Time frame: Baseline (Week 4) up to Day of Choice (approximately 20 weeks)
[DTG/3TC]: Change From Baseline in Total Treatment Satisfaction Score for HIV Treatment Satisfaction Status Questionnaire (HIVTSQs) at Months 6 and 12 or up to Withdrawal
HIVTSQ is a 12-item self-reported scale. Individual items are rated from 0 (very dissatisfied) to 6 (very satisfied) producing a total score ranging from 0 to 66. Higher scores indicate a greater level of participant-reported satisfaction with their current therapy
Time frame: Baseline (Week 4) and at Month 6 and 12
[DTG/3TC]: Change From Baseline in Individual Item Scores for HIVTSQs at Months 6 and 12 or up to Withdrawal
HIVTSQ is a 12-item self-reported scale. Individual items are rated from 0 (very dissatisfied) to 6 (very satisfied).
Time frame: Baseline (Week 4) and at Month 6 and 12
[CAB + RPV LA]: Change From Baseline in Total Treatment Satisfaction Score for HIVTSQs at Months 5 and 11 or up to Withdrawal
HIVTSQ is a 12-item self-reported scale. Individual items are rated from 0 (very dissatisfied) to 6 (very satisfied) producing a total score ranging from 0 to 66. Higher scores indicate a greater level of participant-reported satisfaction with their current therapy
Time frame: Baseline (Week 4) and at Month 5 and 11
[CAB + RPV LA]: Change From Baseline in Individual Item Scores for HIVTSQs at Months 5 and 11 or up to Withdrawal
HIVTSQ is a 12-item self-reported scale. Individual items are rated from 0 (very dissatisfied) to 6 (very satisfied).
Time frame: Baseline (Week 4) and at Month 5 and 11
Change From Baseline in Total Score of HIV Related Symptoms Assessed by Symptom Distress Module (SDM) Through Day of Choice
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 (complete absence of symptom) to 4 (very bothersome symptom). Overall score is calculated as the sum of the scores for each of the 20 items of the questionnaire and ranges from 0 (best health) to 80 (worst health).
Time frame: Baseline (Day 1) and up to and including Day of Choice (approximately 20 weeks)
Change From Baseline in Individual Bothersome Symptoms of HIV Assessed by SDM Through Day of Choice
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 (complete absence of symptom) to 4 (very bothersome symptom).
Time frame: Baseline (Day 1) and up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Change From Baseline in Total Score of HIV Related Symptoms Assessed by SDM at Month 6 and 12
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 (complete absence of symptom) to 4 (very bothersome symptom). Overall score is calculated as the sum of the scores for each of the 20 items of the questionnaire and ranges from 0 (best health) to 80 (worst health).
Time frame: Baseline (Day 1) and at Month 6 and 12
[DTG/3TC]: Change From Baseline in Individual Bothersome Symptoms of HIV Assessed by SDM at Month 6 and 12
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 (complete absence of symptom) to 4 (very bothersome symptom).
Time frame: Baseline (Day 1) and at Month 6 and 12
Change From Baseline in Health-Related Quality of Life Using World Health Organisation Quality of Life Brief version (WHOQoL-HIV-BREF) Through Day of Choice
WHOQoL-HIV-BREF is a 31-item self-reported measure that addresses the 6 quality of life domains including (physical, psychological, level of independence, social relations, environment, spiritual) and 2 general health presence. The scales domain score ranges from 4 to 20. Higher scores indicate a better quality of life.
Time frame: Baseline (Day 1) and up to and including Day of Choice (approximately 20 weeks)
[CAB + RPV LA]: Change From Baseline in Health-Related Quality of Life Using WHOQoL-HIV-BREF at Month 5 and 11
WHOQoL-HIV-BREF is a 31-item self-reported measure that addresses the 6 quality of life domains including (physical, psychological, level of independence, social relations, environment, spiritual) and 2 general health presence. The scales domain score ranges from 4 to 20. Higher scores indicate a better quality of life.
Time frame: Baseline (Day 1) and at Month 5 and 11
[DTG/3TC]: Change From Baseline in Health-Related Quality of Life Using WHOQoL-HIV-BREF at Month 6 and 12
WHOQoL-HIV-BREF is a 31-item self-reported measure that addresses the 6 quality of life domains including (physical, psychological, level of independence, social relations, environment, spiritual) and 2 general health presence. The scales domain score ranges from 4 to 20. Higher scores indicate a better quality of life.
Time frame: Baseline (Day 1) and at Month 6 and 12
Change From Baseline in Anxiety and Depression Score Using Patient Health Questionnaire 9 (PHQ-9) Through Day of Choice
PHQ-9 is a 9-item scale that assesses mood symptoms over past two weeks. Each item is rated from 0 to 3 and yields a total score range of 0-27. Higher score indicates severe depression.
Time frame: Baseline (Day 1) and up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Change From Baseline in Anxiety and Depression Score Using PHQ-9 at Month 6 and 12
PHQ-9 is a 9-item scale that assesses mood symptoms over past two weeks. Each item is rated from 0 to 3 and yields a total score range of 0-27. Higher score indicates severe depression.
Time frame: Baseline (Day 1) and at Month 6 and 12
[CAB + RPV LA]: Change From Baseline in Anxiety and Depression Score Using PHQ-9 at Month 5 and 11
PHQ-9 is a 9-item scale that assesses mood symptoms over past two weeks. Each item is rated from 0 to 3 and yields a total score range of 0-27. Higher score indicates severe depression.
Time frame: Baseline (Day 1) and at Month 5 and 11
Change From Baseline in Anxiety and Depression Score Using General Anxiety Disorder 7 (GAD-7) Through Day of Choice
GAD-7 is a 7-item scale that assesses GAD symptoms over past two weeks. Each item is rated from 0 to 3 and yields a total score range of 0-21. Higher score indicates severe anxiety.
Time frame: Baseline (Day 1) and up to and including Day of Choice (approximately 20 weeks)
[DTG/3TC]: Change From Baseline in Anxiety and Depression Score Using GAD-7 at Month 6 and 12
GAD-7 is a 7-item scale that assesses GAD symptoms over past two weeks. Each item is rated from 0 to 3 and yields a total score range of 0-21. Higher score indicates severe anxiety.
Time frame: Baseline (Day 1) and at Month 6 and 12
[CAB + RPV LA]: Change From Baseline in Anxiety and Depression Score Using GAD-7 at Month 5 and 11
GAD-7 is a 7-item scale that assesses GAD symptoms over past two weeks. Each item is rated from 0 to 3 and yields a total score range of 0-21. Higher score indicates severe anxiety.
Time frame: Baseline (Day 1) and at Month 5 and 11
Percentage of Participants Providing Response to Single Item Bespoke Questions From Baseline to Day of Choice
Bespoke single-item questions are developed by ViiV Healthcare to assess concepts such as stigma, feelings about diagnosis, low mood/excitement relating to treatment.
Time frame: Baseline (Day 1) and Day of Choice (approximately 20 weeks)
[CAB + RPV LA]: Percentage of Participants Providing Response to Single Item Bespoke Questions From Day of Choice to Month 5 and 11
Bespoke single-item questions are developed by ViiV Healthcare to assess concepts such as stigma, feelings about diagnosis, low mood/excitement relating to treatment.
Time frame: Day of Choice (approximately 20 weeks) up to Month 5 and 11
[DTG/3TC]: Percentage of Participants Providing Response to Single Item Bespoke Questions From Day of Choice to Month 6 and 12
Bespoke single-item questions are developed by ViiV Healthcare to assess concepts such as stigma, feelings about diagnosis, low mood/excitement relating to treatment.
Time frame: Day of Choice (approximately 20 weeks) up to Month 6 and 12
[CAB + RPV LA]: Percentage of Participants Providing Response to Assessments Using ViiV Healthcare Developed Single Item Questionnaire From Day of Choice to Month 5 and 11
Bespoke single-item questions developed by ViiV Healthcare to assess long-acting specific concepts such as fear of disclosure of HIV status, adherence anxiety and daily reminder of HIV status.
Time frame: Day of Choice (approximately 20 weeks) up to Month 5 and 11
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Sep 2025, 26 months.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 26 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dolutegravir · Lamivudine · Cabotegravir